logo

FDA Calendar

Share SHARE
Company Name Kite Pharma, Inc.
Drug Name Axicabtagene ciloleucel (KTE-C19) (BLA)
Event Name FDA decision on KTE-C19 for Non-Hodgkin Lymphoma
Event Date 11/29/2017
Outcome Date 10/18/2017
Outcome FDA approved Yescarta (formerly KTE-C19) for Large B-Cell Lymphoma on Oct.18, 2017
Drug Status
Rival Drugs
Market Potential
Other Approvals
News
Return to FDA Calendar